Skip to main content
. 2021 Nov 16;8:754859. doi: 10.3389/fmed.2021.754859

Table 1.

The baseline characteristics of study cohort.

Characteristics Total FFP transfusion Non-FFP transfusion
(N = 3,629) (N = 288) (N = 3,341)
Gender (men/women) 2,023/1,606 182/106 1,841/1,500**
Age (years) 66.6 (53.8–79.7) 68.4 (54.4–80.6) 66.4 (53.8–79.6)
   ≤ 30, n (%) 175 (4.8) 10 (3.5) 165 (4.9)
   >30, ≤ 60, n (%) 1,132 (31.2) 87 (30.2) 1,045 (31.3)
   >60, n (%) 2,322 (64.0) 191 (66.3) 2,131 (63.8)
Alcohol abuse, n (%) 388 (10.7) 41 (14.2) 347 (10.4)*
Culture specimen types
   Blood, n (%) 1,572 (43.3) 109 (37.8) 1,463 (43.8)
   Lung, n (%) 122 (3.4) 8 (2.8) 114 (3.4)
   Urinary system, n (%) 610 (16.8) 49 (17.0) 561 (16.8)
   Gastrointestinal system, n (%) 11 (0.3) 0 (0) 11 (0.3)
Others, n (%) 1,314 (36.2) 122 (42.4) 1,192 (35.7)*
Culture positive, n (%) 476 (13.1) 46 (16.0) 430 (12.9)
Vasopressor (first 24 h), n (%) 1,082 (29.8) 101 (35.1) 981 (29.4)*
Mechanical ventilation (first 24 h), n (%) 1,884 (51.9) 177 (61.5) 1,707 (51.1)**
Renal replacement therapy, n (%) 173 (4.8) 27 (9.4) 146 (4.4)**
GCS score 15 (13–15) 15 (14–15) 15 (13–15)**
SOFA score 5 (3–6) 6 (4–7) 4 (3–6)**
SAPS II score 37.0 (30.0–46.0) 40.5 (34.0–50.0) 37.0 (29.0–46.0)**
Comorbidities
   Congestive heart failure, n (%) 850 (23.4) 72 (25.0) 778 (23.3)
   Cardiac arrhythmias, n (%) 1,089 (30.0) 135 (46.9) 954 (28.6)**
   Hypertension, n (%) 2,140 (59.0) 159 (55.2) 1,981 (59.3)
   Chronic pulmonary, n (%) 788 (21.7) 55 (19.1) 733 (21.9)
   Renal failure, n (%) 634 (17.5) 55 (19.1) 579 (17.3)
   Liver disease, n (%) 347 (9.6) 57 (19.8) 290 (8.7)**
   Solid tumor, n (%) 231 (6.4) 23 (8.0) 208 (6.2)
   Diabetes, n (%) 1,043 (28.7) 78 (27.1) 965 (28.9)
   Hospital LOS (days) 7.7 (4.9–12.7) 10.4 (6.2–16.5) 7.6 (4.8–12.4)**
*

P-value <0.05;

**

P-value <0.01. The data were expressed as median (inter-quartile range) or frequency (percentage). FFP, fresh frozen plasma; GCS, Glasgow coma scale; LOS, length of stay; SAPS II, Simplified Acute Physiology Score II; SOFA, Sequential Organ Failure Assessment.